News | PET-CT | June 12, 2017

Philips Highlights the Value of Advanced Molecular Imaging at SNMMI 2017

Showcases continued commitment to creating innovative solutions that enhance and simplify the clinical decision making path, from diagnosis to treatment, to drive more personalized care

PET/CT

Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation and more personalized care at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 Annual Meeting. Molecular imaging provides insight into molecular and cellular processes in the body, and has the potential to transform healthcare by offering earlier detection and more precise treatment of diseases. Philips continues to bring solutions into the field of nuclear medicine that enhance quantitative accuracy and enable new clinical applications driving more personalized care and workflow efficiencies from diagnosis to treatment.

Nuclear medicine technology has significantly evolved over the years – growing from just scanners to solutions that comprise systems and advanced informatics, for enhanced image quality, quantification and analytics. As value-based care changes the way healthcare organizations approach care delivery, there is a greater need for easy to use, fast and precise imaging. With increased access to better data, clinicians are looking for ways to make that data actionable, especially in terms of customizing patient treatment. Molecular imaging accomplishes that, allowing physicians to make decisions based on the specific molecular and cellular patterns of disease in addition to the patient’s anatomy. 

“Molecular imaging today allows physicians to make decisions with greater insight, precision and confidence, bringing healthcare one step closer to personalized care,” said Kirill Shalyaev, Ph.D., Business Leader, Advanced Molecular Imaging, Philips. “Philips has made a lasting impact in nuclear medicine by providing clinicians with innovations such as Time-of-Flight PET and digital PET/CT, and we remain dedicated to developing solutions that simplify the path to clinical decision making for more confident diagnosis and a faster path to treatment.”

Even with its significant growth in past years, the opportunity for further innovation and growth in nuclear medicine remains, continuing to maximize its value and impact. The latest solutions from Philips include:

Vereos Digital PET/CT – A fully digital PET/CT system featuring Philips proprietary Digital Photon Counting (DPC) technology. Vereos offers improved detectability and characterization of small lesions. The system provides uncompromised detectability and quantification at half the PET dose. Vereos also provides lesion detectability in one tenth of the time. 

Ingenuity TF PET/CT – Leverages Philips’ Astonish TF technology for enhanced image contrast, resolution, and quality. Features Philips’ proprietary xPand5 quantification tools to assist in measuring and monitoring disease progression. These technologies join CT advances, such as iPatient, iDose⁴ and metal artifact reduction for implants (O-MAR), to drive confidence and consistency through personalized patient centric workflow.

IntelliSpace Portal 9.0 – IntelliSpace Portal 9.0 – The latest edition of Philips’ comprehensive, advanced visualization and analysis platform offers quantitative tumor tracking and treatment response tools with a streamlined workflow for follow‐up and analysis in oncology cases. IntelliSpace Portal 9.0 provides enterprise‐wide access to a comprehensive suite of Molecular Imaging processing and review applications for general Nuclear Medicine, SPECT, SPECT/CT and PET/CT.

SPECT Solutions – To fulfill the need for clinically dependable SPECT systems, Philips provides cost-efficient cardiac and general-purpose SPECT solutions that maximize the return on investment.

For more information: www.philips.com 

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
GlobalData: Amazon Poised to Make Huge Strides in Healthcare
News | Radiology Business | August 31, 2018
A new report from data and analytics company GlobalData suggests that Amazon is poised to make huge strides in...
Videos | Treatment Planning | August 28, 2018
A discussion with...
RSNA Announces Pneumonia Detection Machine Learning Challenge
News | Artificial Intelligence | August 27, 2018
The Radiological Society of North America (RSNA) has launched its second annual machine learning challenge. The RSNA...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of